Isabelle Bence‐Bruckler

Author

Also Known As

I Bence-Bruckler, I. Bence-Bruckler, I.A. Bence-Bruckler, Isabelle A. Bence-Bruckler, Isabelle A. Bence‐Bruckler, Isabelle Bence-Bruckler, Isabelle Bence‐Bruckler, Xu, Cong

103

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Ottawa Hospital University of Ottawa Ottawa Hospital Research Institute McGill University Health Centre University Health Network

About

Isabelle Bence‐Bruckler is an author at Ottawa Hospital specializing in medicine, transplantation, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.8K
2	Health Sciences	4	4	200
3	Blood Transplantation	3	3	103
4	Biomedical Engineering	2	2	32
5	Cell Biology	1	1	48

Isabelle Bence‐Bruckler

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Journal of Clinical Oncology	1998	2.8K
Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Neil L. Berinstein, A.J. Grillo-López, Christine A. White, Annals of Oncology Anti-tumor ResponseLymphoid NeoplasiaHematological MalignancySerum RituximabMedicine	1998	520
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, The Lancet Hematological MalignancyLymphoid NeoplasiaRefractory Mantle-cell LymphomaMedicineIbrutinib Versus Temsirolimus	2015	456
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial Harold Atkins, Marjorie A. Bowman, David Allan, The Lancet Cell TherapyTransplantationMarrow TransplantationStem Cell MobilizationAggressive Multiple Sclerosis	2016	320
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler, Blood	2019	124
Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Journal of Clinical Oncology	2013	117
Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation Adam Bryant, Harold Atkins, C. Elizabeth Pringle, JAMA Neurology	2016	100
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study Simon Rule, Wojciech Jurczak, Mats Jerkeman, Leukemia Lymphoid NeoplasiaMantle Cell LymphomaMedicineIbrutinib Versus TemsirolimusSurgical Pathology	2018	95
Effect of FCGR2A and FCGR3A variants on CLL outcome David Dornan, Olivia Spleiss, Ru-Fang Yeh, Blood	2010	59
A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma Mitchell Sabloff, Harold Atkins, Isabelle Bence‐Bruckler, Biology of Blood and Marrow Transplantation	2007	57

Page 1